Patient-reported outcomes in a large North American cohort living with chronic hepatitis B virus: a cross-sectional analysis
Donna M Evon,Hsing-Hua S Lin,Mandana Khalili,Robert J Fontana,Colina Yim,Abdus S Wahed,Michael W Fried,Jay H Hoofnagle,Hepatitis B Research Network (HBRN),Jianghe Niu,Asad Javaid,Bilal Nasir,Ammu Susheela,Imad Nasser,Arley Donovan,Nifasha Rusibamayila,Cara Foley,Alisha C Stahler,Linda Stadheim,John Lake,Philip Lacher,Kathryn Rushing,Debra DeMarco Shaw,Lisa Kessels,Michael K Klebert,Seham Noureldin,Danie La,Lucie Liu,Diana Kaznowski,Jiayun Chen,Fengfei Huang,Doinita Vladutu,Orlando Cerocchi,Debra Rowan,Sheila Bass,Barbara Lilly,Samuel French,Velma Peacock,David Geffen,Marion Peters,Ashley Shobe,Rayshawnda Davis,Romuald Kuras,Claudia Ayala,Ivy Lau,Veronika Podolskaya,Anna von Bakonyi,Nata DeVole,Barbara McKenna,Karen Choi,Kelly Oberhelman,Sravanthi Kaza,Isabel Moran,Leslie Huddleston,Richmond Wong,A Sidney Barritt,Tiffany Marsh,Vikki Metheny,Danielle Cardona,Paula G Smith,Charlotte Hofmann,Alycia Wolfstone,Jody Mooney,Lupita Cardona-Gonzalez,Nancy Fryzek,Elenita Rivera,Nevitt Morris,Vanessa Haynes-Williams,Amy Huang,Catherine Nadal,Jaha Norman-Wheeler,Averell H Sherker,Rebecca J Torrance,Sherry R Hall,Mary E Valiga,Keith Torrey,Danielle Levine,James Keith,Michael Betts,Luis J Montaner,Frani Averbach,Tamara Haller,Regina Hardison,Stephanie Kelley,Christina Lalama,Sharon Lawlor,Manuel Lombardero,Andrew Pelesko,Donna Stoliker,Melissa Weiner,Ella Zadorozny,Qian Zhao
DOI: https://doi.org/10.1111/apt.15618
Abstract:Background: Patient-reported outcomes (PROs) such as health-related quality of life (HRQoL) and symptoms associated with chronic hepatitis B viral (HBV) infection have not been well-described in North American cohorts. Aims: To evaluate several PROs and associations with HBV disease activity markers. Methods: Cross-sectional analysis including 876 adults who completed PRO measures during the Hepatitis B Research Network Adult Cohort Study. Participants on HBV treatment were excluded. Outcomes included: HRQoL using the SF-36 mental component summary and physical component summary scores; symptom burden using a 10-item Total Symptom Checklist and fatigue using an instrument from the Patient-Reported Outcomes Measurement Information System®. Covariates included laboratory markers of disease severity, virological status, comorbidities and medications. Results: Median age was 42 (range: 19-79), 51% were female, 73% Asian, 19% HBeAg (+), 2% had AST-platelet ratio index (APRI) ≥1.5 and 74% without comorbidities. Mean mental component summary T-score = 52, physical component summary T-score = 54 and PROMIS Fatigue T-score = 47. On a scale from 0 (none) to 40 (extreme), the mean Symptom Checklist score = 3 and 25% reported no symptoms. The most frequent symptoms were fatigue (60%), irritability (32%) and itching (32%). Most symptoms were 'a little bit' bothersome. In multivariable regressions, APRI ≥1.50 and more comorbidities were associated with worse patient-reported outcomes; virological markers were not. Adding the Total Symptom Checklist score to original regression models increased explanation of variation in the mental component summary score from 4% to 44% and the Physical Component Summary Score from 17% to 34%. Conclusions: Untreated North American HBV patients with mild liver disease report favourable health-related quality of life and minimal symptoms. HBV does not impact health-related quality of life unless advanced liver disease or comorbidities are present. High symptom burden explains substantial variation in health-related quality of life. (CT.gov identifier: NCT01263587).